Q1 EPS Forecast for Sagimet Biosciences Increased by Analyst

Sagimet Biosciences Inc. (NASDAQ:SGMT) – HC Wainwright boosted their Q1 2025 EPS estimates for shares of Sagimet Biosciences in a research note issued to investors on Thursday, March 13th. HC Wainwright analyst E. Arce now forecasts that the company will earn ($1.00) per share for the quarter, up from their previous estimate of ($1.08). HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($1.34) EPS, FY2025 earnings at ($4.86) EPS, FY2026 earnings at ($5.77) EPS, FY2027 earnings at ($5.44) EPS, FY2028 earnings at ($3.74) EPS and FY2029 earnings at ($2.29) EPS.

Sagimet Biosciences (NASDAQ:SGMT) last issued its earnings results on Wednesday, March 12th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.15.

Separately, Oppenheimer assumed coverage on shares of Sagimet Biosciences in a report on Friday, December 6th. They set an “outperform” rating and a $30.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Sagimet Biosciences Stock Up 1.1 %

NASDAQ SGMT opened at $3.78 on Monday. The stock has a market capitalization of $115.95 million, a PE ratio of -2.64 and a beta of 2.57. Sagimet Biosciences has a 12-month low of $2.39 and a 12-month high of $7.38. The company has a 50 day moving average price of $4.22 and a two-hundred day moving average price of $4.47.

Institutional Trading of Sagimet Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of SGMT. Wells Fargo & Company MN acquired a new position in Sagimet Biosciences in the 4th quarter valued at $31,000. Jacksonville Wealth Management LLC acquired a new stake in shares of Sagimet Biosciences in the fourth quarter valued at about $45,000. Summit Financial Wealth Advisors LLC bought a new position in shares of Sagimet Biosciences in the fourth quarter worth about $61,000. Shay Capital LLC acquired a new position in shares of Sagimet Biosciences during the 4th quarter worth about $87,000. Finally, American Century Companies Inc. acquired a new position in shares of Sagimet Biosciences during the 4th quarter worth about $90,000. 87.86% of the stock is currently owned by institutional investors and hedge funds.

About Sagimet Biosciences

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.